Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Liver fibrosis
Ramón Bataller, David A. Brenner
Ramón Bataller, David A. Brenner
Published February 1, 2005
Citation Information: J Clin Invest. 2005;115(2):209-218. https://doi.org/10.1172/JCI24282.
View: Text | PDF | Corrigendum
Science in Medicine Article has an altmetric score of 213

Liver fibrosis

  • Text
  • PDF
Abstract

Liver fibrosis is the excessive accumulation of extracellular matrix proteins including collagen that occurs in most types of chronic liver diseases. Advanced liver fibrosis results in cirrhosis, liver failure, and portal hypertension and often requires liver transplantation. Our knowledge of the cellular and molecular mechanisms of liver fibrosis has greatly advanced. Activated hepatic stellate cells, portal fibroblasts, and myofibroblasts of bone marrow origin have been identified as major collagen-producing cells in the injured liver. These cells are activated by fibrogenic cytokines such as TGF-β1, angiotensin II, and leptin. Reversibility of advanced liver fibrosis in patients has been recently documented, which has stimulated researchers to develop antifibrotic drugs. Emerging antifibrotic therapies are aimed at inhibiting the accumulation of fibrogenic cells and/or preventing the deposition of extracellular matrix proteins. Although many therapeutic interventions are effective in experimental models of liver fibrosis, their efficacy and safety in humans is unknown. This review summarizes recent progress in the study of the pathogenesis and diagnosis of liver fibrosis and discusses current antifibrotic strategies.

Authors

Ramón Bataller, David A. Brenner

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 Total
Citations: 65 147 153 179 178 149 133 138 131 150 152 119 102 102 88 73 53 44 27 22 2 2207
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2007 (27)

Title and authors Publication Year
Models of Liver Fibrosis: Exploring the dynamic nature of inflammation and repair in a solid organ
J. P. Iredale
Journal of Clinical Investigation 2007
Common and Unique Mechanisms Regulate Fibrosis in Various Fibroproliferative Diseases
Thomas A. Wynn
Journal of Clinical Investigation 2007
NOX in liver fibrosis
SD Minicis, DA Brenner
Archives of Biochemistry and Biophysics 2007
Fibrosis and cancer: Do myofibroblasts come also from epithelial cells via EMT?
DC Radisky, PA Kenny, MJ Bissell
Journal of Cellular Biochemistry 2007
Bioconjugation of Oligonucleotides for Treating Liver Fibrosis
Z Ye, HS Houssein, RI Mahato
Oligonucleotides 2007
The Effect of Ras Inhibition on the Proliferation, Apoptosis and Matrix Metalloproteases Activity in Rat Hepatic Stellate Cells
I Zvibel, D Bar-Zohar, Y Kloog, R Oren, S Reif
Digestive Diseases and Sciences 2007
The Myofibroblast
B Hinz, SH Phan, VJ Thannickal, A Galli, ML Bochaton-Piallat, G Gabbiani
The American Journal of Pathology 2007
Inflammation and Repair in Viral Hepatitis C
MG Neuman, K Sha, R Esguerra, S Zakhari, RE Winkler, N Hilzenrat, J Wyse, CL Cooper, D Seth, MD Gorrell, PS Haber, GW McCaughan, MA Leo, CS Lieber, M Voiculescu, E Buzatu, C Ionescu, J Dudas, B Saile, G Ramadori
Digestive Diseases and Sciences 2007
Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options
OA Gressner, R Weiskirchen, AM Gressner
Comparative hepatology 2007
Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality
OA Gressner, R Weiskirchen, AM Gressner
Journal of Cellular and Molecular Medicine 2007
A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis
P Fickert, U Stöger, A Fuchsbichler, T Moustafa, HU Marschall, AH Weiglein, O Tsybrovskyy, H Jaeschke, K Zatloukal, H Denk, M Trauner
The American Journal of Pathology 2007
Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-β as major players and therapeutic targets
Gressner AM, Weiskirchen R
Journal of Cellular and Molecular Medicine 2007
Treatment of fibrosis in nonalcoholic fatty liver disease.
Hoteit MA, Anania FA
Current Gastroenterology Reports 2007
Different profiles of Ca2+responses to endothelin-1 and PDGF in liver myofibroblasts during the process of cell differentiation
N Kojima, M Hori, T Murata, Y Morizane, H Ozaki
British Journal of Pharmacology 2007
A ribosomal S-6 kinase-mediated signal to C/EBP-beta is critical for the development of liver fibrosis
M Buck, M Chojkier
PloS one 2007
Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells
E Novo, S Cannito, E Zamara, LV di Bonzo, A Caligiuri, C Cravanzola, A Compagnone, S Colombatto, F Marra, M Pinzani, M Parola
The American Journal of Pathology 2007
Bone Morphogenetic Protein 7 is Elevated in Patients with Chronic Liver Disease and Exerts Fibrogenic Effects on Human Hepatic Stellate Cells
F Tacke, E Gäbele, F Bataille, RF Schwabe, C Hellerbrand, F Klebl, RH Straub, T Luedde, MP Manns, C Trautwein, DA Brenner, J Schölmerich, B Schnabl
Digestive Diseases and Sciences 2007
Simple Tests to Predict Hepatic Fibrosis in Nonalcoholic Chronic Liver Diseases
Shin WG, Park SH, Jun SY, Jung JO, Moon JH, Kim JP, Kim KO, Park CH, Hahn TH, Yoo KS, Kim JH, Park CK
Gut and Liver 2007
Gene Modulation for Treating Liver Fibrosis
Cheng K, Mahato RI
Critical reviews in therapeutic drug carrier systems 2007
Adeno-associated virus vector-mediated production of hepatocyte growth factor attenuates liver fibrosis in mice
Suzumura K, Hirano T, Son G, Iimuro Y, Mizukami H, Ozawa K, Fujimoto J
Hepatology International 2007
Sonic Hedgehog Is An Autocrine Viability Factor for Myofibroblastic Hepatic Stellate Cells
Yang L, Wang Y, Mao H, Fleig S, Omenetti A, Brown KD, Sicklick JK, Li YX, Diehl AM
Journal of Hepatology 2007
Cholangiocytes with Mesenchymal Features Contribute to Progressive Hepatic Fibrosis of the Polycystic Kidney Rat
Sato Y, Harada K, Ozaki S, Furubo S, Kizawa K, Sanzen T, Yasoshima M, Ikeda H, Sasaki M, Nakanuma Y
The American Journal of Pathology 2007
Tumor Necrosis Factor-α 308.2 Polymorphism Is Associated with Advanced Hepatic Fibrosis and Higher Risk for Hepatocellular Carcinoma
Jen-Eing J, Jung-Fa T, Lee-Yea C, Mei-Shang H, Zu-Yau L, Min-Yuh H, Shin-Chern C, Wan-Lung C, Liang-Yen W, Ming-Lung Y, Chia-Yen D, Jan-Gowth C
Neoplasia (New York, N.Y.) 2007
Pathophysiological characteristics of dimethylnitrosamine-induced liver fibrosis in acute and chronic injury models: a possible contribution of KLF5 to fibrogenic responses.
Ohara F, Nii A, Sakiyama Y, Tsuchiya M, Ogawa S
Digestive Diseases and Sciences 2007
Immunological response in alcoholic liver disease.
Duryee MJ, Klassen LW, Thiele GM
World Journal of Gastroenterology 2007
Role of iron in hepatic fibrosis: one piece in the puzzle.
Philippe MA, Ruddell RG, Ramm GA
World Journal of Gastroenterology 2007
Identification and functional characterization of the hepatic stellate cell CD38 cell surface molecule.
March S, Graupera M, Rosa Sarrias M, Lozano F, Pizcueta P, Bosch J, Engel P
The American Journal of Pathology 2007

← Previous 1 2 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 20 news outlets
Blogged by 5
Referenced in 1 policy sources
Posted by 7 X users
Referenced in 31 patents
On 2 Facebook pages
Referenced in 1 Wikipedia pages
Referenced in 2 clinical guideline sources
1396 readers on Mendeley
6 readers on CiteULike
See more details